Ormicton (Finasteride)

Finasteride, the active ingredient in Ormicton, is a 5‑α‑reductase inhibitor presented as a tablet for oral use. It is primarily prescribed for conditions related to androgen‑dependent tissue growth in adult males.

GNH USA supplies Ormicton as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Ormicton (finasteride) acts through the inhibition of the 5‑alpha‑reductase enzyme pathway for benign prostatic conditions and androgen‑dependent hair loss. - Benign prostatic hyperplasia (BPH): Reduces prostate size and improves urinary flow. - Male pattern hair loss (androgenetic alopecia): Slows   t   "); -  ");  "  \